By A/Prof Tony Caccetta and Dr Helena Collgros, Dermatologists
Immunotherapy has transformed cancer treatment by shifting the focus from directly killing cancer cells to activating the immune system to fight cancer – improving survival in many advanced cancers without chemotherapy related side effects.
However, immunotherapy related adverse events (irAEs) are common and may be serious or life-threatening.
Immune checkpoint inhibitors (ICIs), for example ipilimumab, nivolumab, pembrolizumab, atezolizumab, may cause cutaneous toxicity in 30-50% of patients. Often occurring in the first few weeks - months of treatment, the onset can be unpredictable, occuring at any time....
Immunotherapy has transformed cancer treatment by shifting the focus from directly killing cancer cells to activating the immune system to fight cancer – improving survival in many advanced cancers without chemotherapy related side effects.
However, immunotherapy related adverse events (irAEs) are common and may be serious or life-threatening.
Immune checkpoint inhibitors (ICIs), for example ipilimumab, nivolumab, pembrolizumab, atezolizumab, may cause cutaneous toxicity in 30-50% of patients. Often occurring in the first few weeks - months of treatment, the onset can be unpredictable, occuring at any time....
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.